Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 2, Issue 4 (2013)

Evaluation of the Effect of Angiotensin-Converting Enzyme Inhibitors and the Angiotensin II Receptor Blockers on the Dynamics of Mitogenic Growth Factors, Apoptosis Inducers and Pulmonary Artery Systolic Pressure in Patients with Chronic Pulmonary Heart Disease

Author(s):
Vitaliy Seredyuk
Abstract:
The dynamics of mitogenic growth factors was investigated, including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and apoptosis inducer Fas-Ligand (FasL), and the level of pulmonary artery systolic pressure (PASP) under the influence of angiotensin-converting enzyme (ACE) enalapril, and the angiotensin II receptor blocker (ARB) candesartan and their combined use in patients with chronic pulmonary heart disease (CPHD). The study involved 282 patients with CPHD, including 55 (19.5%) with compensated and 227 (80.5%) with decompensated CPHD and chronic heart failure (CHF) NYHA Class II-IV. It was found that ACE inhibitor enalapril and the angiotensin II receptor blocker candesartan reduce levels of mitogenic growth factors bFGF, VEGF, apoptosis inducer Fas-Ligand, and PASP in patients with CPHD. Clinical efficacy of long-term (over 6 months) combined use of ACE inhibitor enalapril and the angiotensin II receptor blocker candesartan on the background of a basic therapy in patients with decompensated CPHD and CHF NYHA Class III - IV judging by the dynamics of bFGF, VEGF, FasL , and PASP levels is more pronounced, than during the same treatment but without the angiotensin II receptor blocker.
fig 1
Fig.: fig 1
Pages: 61-69  |  1846 Views  92 Downloads


The Pharma Innovation Journal
How to cite this article:
Vitaliy Seredyuk. Evaluation of the Effect of Angiotensin-Converting Enzyme Inhibitors and the Angiotensin II Receptor Blockers on the Dynamics of Mitogenic Growth Factors, Apoptosis Inducers and Pulmonary Artery Systolic Pressure in Patients with Chronic Pulmonary Heart Disease. Pharma Innovation 2013;2(4):61-69.

Call for book chapter